IL171613A - Antisolvent solidification process - Google Patents
Antisolvent solidification processInfo
- Publication number
- IL171613A IL171613A IL171613A IL17161305A IL171613A IL 171613 A IL171613 A IL 171613A IL 171613 A IL171613 A IL 171613A IL 17161305 A IL17161305 A IL 17161305A IL 171613 A IL171613 A IL 171613A
- Authority
- IL
- Israel
- Prior art keywords
- process according
- organic
- compound
- particles
- inorganic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 15
- 239000012296 anti-solvent Substances 0.000 title claims 8
- 238000007711 solidification Methods 0.000 title claims 3
- 230000008023 solidification Effects 0.000 title claims 3
- 239000002245 particle Substances 0.000 claims 11
- 150000002484 inorganic compounds Chemical class 0.000 claims 8
- 150000002894 organic compounds Chemical class 0.000 claims 8
- 239000012528 membrane Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 229910010272 inorganic material Inorganic materials 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000011248 coating agent Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 239000008247 solid mixture Substances 0.000 claims 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 238000010924 continuous production Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 1
- 229960004976 desogestrel Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960002941 etonogestrel Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001728 nano-filtration Methods 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 claims 1
- 229960001023 tibolone Drugs 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003623 transition metal compounds Chemical class 0.000 claims 1
- -1 transition metal salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0063—Control or regulation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
- B01D9/0054—Use of anti-solvent
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/22—Preparation in the form of granules, pieces, or other shaped products
- C01D3/24—Influencing the crystallisation process
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Steroid Compounds (AREA)
- Glanulating (AREA)
- Colloid Chemistry (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46676103P | 2003-04-29 | 2003-04-29 | |
| PCT/EP2004/004506 WO2004096405A1 (en) | 2003-04-29 | 2004-04-28 | Antisolvent solidification process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL171613A true IL171613A (en) | 2010-02-17 |
Family
ID=33418418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL171613A IL171613A (en) | 2003-04-29 | 2005-10-27 | Antisolvent solidification process |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20060182808A1 (enExample) |
| EP (1) | EP1620193B1 (enExample) |
| JP (1) | JP5207432B2 (enExample) |
| KR (1) | KR20060006949A (enExample) |
| CN (1) | CN100434133C (enExample) |
| AR (1) | AR044140A1 (enExample) |
| AT (1) | ATE406946T1 (enExample) |
| AU (1) | AU2004234057A1 (enExample) |
| BR (1) | BRPI0409860A (enExample) |
| CA (1) | CA2523883C (enExample) |
| CL (1) | CL2004000912A1 (enExample) |
| DE (1) | DE602004016311D1 (enExample) |
| ES (1) | ES2312996T3 (enExample) |
| IL (1) | IL171613A (enExample) |
| MX (1) | MXPA05011626A (enExample) |
| MY (1) | MY141189A (enExample) |
| NO (1) | NO20055607L (enExample) |
| NZ (1) | NZ543772A (enExample) |
| RU (1) | RU2339364C2 (enExample) |
| TW (1) | TW200500095A (enExample) |
| WO (1) | WO2004096405A1 (enExample) |
| ZA (1) | ZA200509597B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006272438B2 (en) * | 2005-07-15 | 2011-08-04 | Map Pharmaceuticals, Inc. | Method of particle formation |
| EP1906919A4 (en) * | 2005-07-15 | 2012-12-26 | Map Pharmaceuticals Inc | MULTIPLE ACTIVE PHARMACEUTICAL PRINCIPLES COMBINED IN DISCRETE INHALATION PARTICLES AND THEIR FORMULATIONS |
| US7942990B2 (en) | 2006-12-18 | 2011-05-17 | Daicel Chemical Industries, Ltd. | Hybrid inflator |
| EP2124633B1 (en) * | 2007-01-22 | 2012-03-07 | Cargill, Incorporated | Method of producing purified rebaudioside a compositions using solvent/antisolvent crystallization |
| GB0705159D0 (en) * | 2007-03-19 | 2007-04-25 | Prosonix Ltd | Process for making crystals |
| FI120527B (fi) * | 2007-06-18 | 2009-11-30 | Crisolteq Oy | Talteenottomenetelmä |
| GB0711680D0 (en) * | 2007-06-18 | 2007-07-25 | Prosonix Ltd | Process |
| US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
| TWI466709B (zh) * | 2011-07-20 | 2015-01-01 | Nat Univ Chung Hsing | From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9452930B2 (en) * | 2013-11-04 | 2016-09-27 | New Jersey Institute Of Technology | System and method for continuous polymer coating of particles |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| PT108368B (pt) * | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CN106853295A (zh) * | 2015-12-09 | 2017-06-16 | 北大方正集团有限公司 | 一种基于膜分散的结晶方法 |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10881123B2 (en) * | 2017-10-27 | 2021-01-05 | Frito-Lay North America, Inc. | Crystal morphology for sodium reduction |
| JP6761560B2 (ja) * | 2018-06-14 | 2020-09-23 | 日揮株式会社 | 晶析装置及び晶析方法 |
| CN119679728A (zh) * | 2018-12-28 | 2025-03-25 | 四川科伦药物研究院有限公司 | 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂 |
| CN111234431A (zh) * | 2020-03-31 | 2020-06-05 | 宁夏颐星新材料科技有限公司 | 一种消泡型聚乙烯醇粉末的生产工艺 |
| GB202004824D0 (en) | 2020-04-01 | 2020-05-13 | Naturbeads Ltd | Biopolymer particle preparation |
| GB202011836D0 (en) * | 2020-07-30 | 2020-09-16 | Micropore Tech Limited | Crystallisation methods |
| CN115777906A (zh) * | 2021-09-10 | 2023-03-14 | 吉林大学 | 氯化钠纳微米粒子及其制备方法和应用 |
| AU2023408533A1 (en) | 2022-12-22 | 2025-08-07 | Nanomi B.V. | Process for preparing stable nanoparticle and composition thereof |
| CN117942426B (zh) * | 2024-03-22 | 2024-05-31 | 四川大学 | 一种具有取向孔道结构的多级多孔材料及其制备方法和应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2716453B1 (fr) * | 1994-02-22 | 1996-03-29 | Rhone Poulenc Agrochimie | Procédé de sulfinylation de composés hétérocycliques. |
| US4089843A (en) * | 1976-09-20 | 1978-05-16 | The Upjohn Company | Precipitating polymers in powder form |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
| JPH0672528B2 (ja) * | 1985-07-16 | 1994-09-14 | 三信工業株式会社 | 船舶のエンジン |
| RU2026670C1 (ru) * | 1988-10-05 | 1995-01-20 | Дзе Апджон Компани | Способ получения тонкодисперсного твердого фармацевтического вещества |
| US5269926A (en) * | 1991-09-09 | 1993-12-14 | Wisconsin Alumni Research Foundation | Supported microporous ceramic membranes |
| FR2658498B1 (fr) * | 1990-02-19 | 1992-05-15 | Atochem | Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits. |
| JP2555475B2 (ja) * | 1990-10-16 | 1996-11-20 | 工業技術院長 | 無機質微小球体の製造方法 |
| JP2816597B2 (ja) * | 1990-11-28 | 1998-10-27 | 富士写真フイルム株式会社 | 溶液の均一混合装置および弾性体多孔膜 |
| IE71202B1 (en) * | 1990-12-17 | 1997-02-12 | Akzo Nv | Progestagen-only contraceptive |
| WO1993000156A1 (fr) * | 1991-06-29 | 1993-01-07 | Miyazaki-Ken | Emulsions monodispersees simples et doubles et procede de production |
| JP3722293B2 (ja) * | 1991-12-18 | 2005-11-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 新規な薬学的固体分散物 |
| DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
| NZ276277A (en) * | 1993-11-08 | 1998-04-27 | Gillette Co | Antiperspirant compound, in aerogel form, being an aluminium salt, a zirconium salt or an aluminium-zirconium salt |
| JP3492787B2 (ja) * | 1994-04-15 | 2004-02-03 | 信越化学工業株式会社 | 固形製剤のコーティング用水性エマルジョンの濃縮方法 |
| US6387399B1 (en) * | 1994-12-02 | 2002-05-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulated bioactive agents and method of making |
| SE9501384D0 (sv) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| US5876480A (en) * | 1996-02-20 | 1999-03-02 | The United States Of America As Represented By The Secretary Of The Navy | Synthesis of unagglomerated metal nano-particles at membrane interfaces |
| GB9610955D0 (en) * | 1996-05-24 | 1996-07-31 | Hercules Inc | Sizing composition |
| IL123984A (en) * | 1997-04-22 | 2004-09-27 | Akzo Nobel Nv | Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable |
| US5879715A (en) * | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
| EP1071402B1 (en) * | 1998-04-09 | 2006-09-13 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| SE9801287D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Incorporation of active substances in carrier matrixes |
| US6113795A (en) * | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| IN191236B (enExample) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6780507B2 (en) * | 2000-02-09 | 2004-08-24 | Analytical Research Systems, Inc. | Hydrocapsules and method of preparation thereof |
| US6623761B2 (en) * | 2000-12-22 | 2003-09-23 | Hassan Emadeldin M. | Method of making nanoparticles of substantially water insoluble materials |
| GB0102075D0 (en) * | 2001-01-26 | 2001-03-14 | Astrazeneca Ab | Process |
| US20030049323A1 (en) * | 2001-08-29 | 2003-03-13 | Hitt James E. | Process to precipitate drug particles |
| HRP20040334A2 (en) * | 2001-10-10 | 2004-08-31 | Boehringer Ingelheim Pharma | Powder processing with pressurized gaseous fluids |
| US6890592B2 (en) * | 2002-03-13 | 2005-05-10 | Appleton Papers Inc. | Uniform microcapsules |
| US6966990B2 (en) * | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
-
2004
- 2004-04-28 JP JP2006505309A patent/JP5207432B2/ja not_active Expired - Fee Related
- 2004-04-28 EP EP04729890A patent/EP1620193B1/en not_active Expired - Lifetime
- 2004-04-28 NZ NZ543772A patent/NZ543772A/en unknown
- 2004-04-28 CA CA2523883A patent/CA2523883C/en not_active Expired - Fee Related
- 2004-04-28 AU AU2004234057A patent/AU2004234057A1/en not_active Abandoned
- 2004-04-28 KR KR1020057020462A patent/KR20060006949A/ko not_active Ceased
- 2004-04-28 AT AT04729890T patent/ATE406946T1/de not_active IP Right Cessation
- 2004-04-28 CN CNB2004800113339A patent/CN100434133C/zh not_active Expired - Fee Related
- 2004-04-28 DE DE602004016311T patent/DE602004016311D1/de not_active Expired - Lifetime
- 2004-04-28 WO PCT/EP2004/004506 patent/WO2004096405A1/en not_active Ceased
- 2004-04-28 ES ES04729890T patent/ES2312996T3/es not_active Expired - Lifetime
- 2004-04-28 US US10/553,211 patent/US20060182808A1/en not_active Abandoned
- 2004-04-28 BR BRPI0409860-9A patent/BRPI0409860A/pt not_active IP Right Cessation
- 2004-04-28 RU RU2005136983/15A patent/RU2339364C2/ru active
- 2004-04-28 MX MXPA05011626A patent/MXPA05011626A/es active IP Right Grant
- 2004-04-29 AR ARP040101476A patent/AR044140A1/es active IP Right Grant
- 2004-04-29 MY MYPI20041619A patent/MY141189A/en unknown
- 2004-04-29 CL CL200400912A patent/CL2004000912A1/es unknown
- 2004-04-29 TW TW093112056A patent/TW200500095A/zh unknown
-
2005
- 2005-10-27 IL IL171613A patent/IL171613A/en not_active IP Right Cessation
- 2005-11-28 NO NO20055607A patent/NO20055607L/no not_active Application Discontinuation
- 2005-11-28 ZA ZA200509597A patent/ZA200509597B/en unknown
-
2011
- 2011-05-03 US US13/099,926 patent/US20110268806A1/en not_active Abandoned
-
2012
- 2012-05-25 US US13/481,088 patent/US20120232296A1/en not_active Abandoned
-
2013
- 2013-01-09 US US13/737,061 patent/US20130131029A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100434133C (zh) | 2008-11-19 |
| ATE406946T1 (de) | 2008-09-15 |
| ES2312996T3 (es) | 2009-03-01 |
| DE602004016311D1 (de) | 2008-10-16 |
| EP1620193B1 (en) | 2008-09-03 |
| NO20055607D0 (no) | 2005-11-28 |
| CN1780670A (zh) | 2006-05-31 |
| AU2004234057A1 (en) | 2004-11-11 |
| CA2523883C (en) | 2012-01-03 |
| NZ543772A (en) | 2009-05-31 |
| MXPA05011626A (es) | 2006-01-23 |
| US20060182808A1 (en) | 2006-08-17 |
| US20110268806A1 (en) | 2011-11-03 |
| RU2005136983A (ru) | 2006-03-20 |
| HK1088268A1 (en) | 2006-11-03 |
| JP2006524565A (ja) | 2006-11-02 |
| US20130131029A1 (en) | 2013-05-23 |
| US20120232296A1 (en) | 2012-09-13 |
| TW200500095A (en) | 2005-01-01 |
| BRPI0409860A (pt) | 2006-05-16 |
| NO20055607L (no) | 2005-11-28 |
| AR044140A1 (es) | 2005-08-24 |
| CL2004000912A1 (es) | 2005-02-04 |
| WO2004096405A1 (en) | 2004-11-11 |
| CA2523883A1 (en) | 2004-11-11 |
| KR20060006949A (ko) | 2006-01-20 |
| RU2339364C2 (ru) | 2008-11-27 |
| ZA200509597B (en) | 2006-12-27 |
| MY141189A (en) | 2010-03-31 |
| JP5207432B2 (ja) | 2013-06-12 |
| EP1620193A1 (en) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL171613A (en) | Antisolvent solidification process | |
| JP2006524565A5 (enExample) | ||
| DE69105106T2 (de) | Im wasser schnell suspendierbare pharmazeutische zusammensetzung. | |
| EP0050480B1 (en) | Long lasting multi-layered film preparation and process for its production | |
| DE3686275T2 (de) | Praeparate mit verzoegerter freisetzung. | |
| TWI435718B (zh) | The method for producing a wax-containing matrix particle containing a drug is carried out by using an extruder in the method and a sustained-release preparation containing Cilostazol | |
| DE69231359T2 (de) | Ibuprofen-salz enthaltende pharmazeutische zusammensetzung | |
| DE60204897T2 (de) | Kristalline freie base von clindamycin | |
| DE3327449A1 (de) | Eine neue form von cefuroximester, verfahren zu dessen herstellung und diesen enthaltende zusammensetzung | |
| EP2120880A2 (de) | Pellets mit magensaftresistenter wirkstoff-matrix | |
| DE10304403A1 (de) | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung | |
| CN1150757A (zh) | 生产活性物质组合物的方法以及活性物质组合物 | |
| UA79930C2 (en) | Crystalline composition containing escitalopram | |
| CH647675A5 (de) | Verfahren zur herstellung von pharmazeutisch aktive verbindungen enthaltenden mikrokapseln. | |
| DE3400106A1 (de) | Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung | |
| AU2021203748A1 (en) | Compositions and methods for the treatment of cancer | |
| CA2372025A1 (en) | Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix | |
| CN104887633B (zh) | 一种利伐沙班片剂及其制备方法 | |
| EP0226588B1 (en) | Process for preparation of a solid form for oral use based on nifedipine with controlled release of the active substance | |
| EP1318805A2 (en) | Pharmaceutical composition containing citalopram | |
| WO1999029308A2 (de) | Methode zur bekämpfung der fettleibigkeit | |
| DE69632787T2 (de) | Pharmazeutische pellets | |
| WO2000033819A1 (de) | Verfahren zur herstellung von agglomeraten mit kern-schale-struktur | |
| GB1576731A (en) | Process for the preparation of sodium amoxycillin | |
| CN107281167A (zh) | 一种苯佐那酯软胶囊及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |